Clinical Trials
33 trialsROWAN
Boston Scientific Corporation
TRIDENT-1
Turning Point Therapeutics, Inc.
INDIGO
Boston Scientific Corporation
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Stanford University
DETERMINE
Cancer Research UK
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences, Inc
DETERMINE
Cancer Research UK
DETERMINE
Cancer Research UK
DETERMINE
Cancer Research UK
ARROW
Hoffmann-La Roche
IntenSify
German Cancer Research Center
intERsection
Hospital Universitario 12 de Octubre
TheraSphere Post-Approval Study to Calculate the Radiation-absorbed Dose of Tc-99m MAA.
Boston Scientific Corporation
OPTIMA
Imunon
A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
Theseus Pharmaceuticals
CanStem303C
Sumitomo Pharma America, Inc.
CanStem111P
Sumitomo Pharma America, Inc.
SEPTRALU
Sociedad Española de Medicina Nuclear e Imagen Molecular
ALTER-E005
Jiangxi Provincial Cancer Hospital
Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors
Syndax Pharmaceuticals
Lesion SSL
Hospices Civils de Lyon
Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Syndax Pharmaceuticals
CLEAR-C
Zhejiang University
Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
MERCURY II
Royal Marsden NHS Foundation Trust
Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks
Royal Marsden NHS Foundation Trust
MARVEL
Royal Marsden NHS Foundation Trust
Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors
Yale University
NET
Assistance Publique - Hôpitaux de Paris
A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors
Centocor, Inc.
Fibrolam
Assistance Publique - Hôpitaux de Paris
Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)
Abbott
Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate Hepatocellular Carcinoma
Shandong Cancer Hospital and Institute